You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Lightweight Electromagnetic (EM) Shielding Structural Materials

    SBC: Conductive Composites Company, L.L.C.            Topic: AF121111

    BLANK

    SBIR Phase II 2019 Department of DefenseAir Force
  2. Optimization of the Ferrous Chloride (FeCl2) and Compliance MX Treatment Chemistries in Managing Chelated Industrial Waste Streams

    SBC: CACHE ENVIRONMENTAL LABORATORIES, PC            Topic: AF121219

    With growing regulatory concern over the release of waterborne industrial pollutants, the US Environmental Protection Agency has identified metal finishing as an industrial operation whose pollutant discharge poses a significant threat to public health and the environment. Currently, the US Department of Defense (DoD) weapon system operations rely on metal hydroxide precipitation to treat metal fi ...

    SBIR Phase II 2019 Department of DefenseAir Force
  3. Non-DoD

    SBC: Sarcos Group LC            Topic: N96T002

    In this effort, powered upper extremity (two arms and modular, unpowered, application-specific end effectors) of a wearable exoskeleton robot used to augment human performance while performing logistical tasks will be developed, tested and demonstrated. The new exoskeleton, referred to as XO-MAX(UE)-L exoskeleton, will be integrated with the Lower Extremity, XO-MAX(LE)-L exoskeleton, developed und ...

    SBIR Phase II 2019 Department of DefenseAir Force
  4. Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma

    SBC: OCULO THERAPY LLC            Topic: NEI

    Glaucoma is the leading cause of irreversible blindness in the world. Elevated intraocular pressure (IOP) is the most significant risk factor contributing to death of retinal neurons and resulting visual field loss in primary open angle glaucoma, the most common form of glaucoma. The current standard of care for glaucoma includes IOP- lowering medications delivered topically as eye drops, which de ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Targeted Intraceptors for Macular Degeneration

    SBC: Iveena Delivery Systems, Inc.            Topic: NEI

    Project Summary Age-related Macular Degeneration (AMD) is the leading cause of blindness in US. It affects over 25% of the people by the age 80. An estimated 25 million people are afflicted with AMD worldwide. Neovascular or “wet” AMD, which affects 10%–15% of AMD patients, is a rapid form of the disease and progresses to blindness if left untreated. Histopathologically, the disease involves ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Accessible And Robust Tools for Glycosaminoglycan Profiling

    SBC: ECHELON BIOSCIENCES, INC.            Topic: 300

    Glycosaminoglycans (GAGs) are polysaccharides composed of a repeated disaccharide subunit and known to be important for the maintenance of structure and mechanical properties of the extracellular matrix. More recently, changes in the content, size, and composition of GAGs have been found to play biological roles in disease processes as well. For example, chondroitin sulfate (CS) is the most abunda ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Natural Products-Based High Throughput Screen: Identification of Correctors of Cystic Fibrosis Misfolding Mutants

    SBC: Synthetic Biodesign, LLC            Topic: NCCIH

    Natural products or their derivatives have accounted for most of our current drugsdemonstrating their unique status asprivilegedmolecules that are well adapted for therapeutic useHowevernatural products have previously been unsuitable for modernhigh throughputHTdrug discovery screening approachesand as suchwere long ago abandoned in drug discovery programs of large pharmaThe substitute has been hi ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Identifying the precursor to oxytocin-induced uterine tachysystole by monitoring with uterine EMG

    SBC: PreTel, Inc.            Topic: NICHD

    Approximatelyof all women in the USoverannuallyare exposed to IV oxytocin at some point during labor to increase the frequency and strength of uterine contractionsOxytocin is classified as a high alert medication requiring clinical vigilanceOxytocin is generally safebut adverse outcomes arise when contractions become too frequenta condition called tachysystoleTachysystole is associated with fetal ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics

    SBC: SAB CAPRA, LLC            Topic: NIAID

    Project Summary/Abstract The ultimate goal of this phase II STTR proposal is to expand the capabilities of SABandapos;s diversitAb™ platform by continuing advanced development of Transchromosomic goats (TcGs). This will be accomplished by producing male and female goat endogenous immunoglobulin gene knockout cell lines that contain SAB Capraandapos;s human artificial chromosome (HAC) which encod ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Dual-Tracer Cardiac PET Imaging

    SBC: MULTIFUNCTIONAL IMAGING, LLC            Topic: NHLBI

    Abstract Radiologic imaging plays an important role in the care of patients with a variety of heart diseasesand the ways in which imaging are used for cardiac patients is rapidly evolvingIn the pasthigh end cardiac imaging has been dominated by rest stress procedures for evaluating myocardial perfusion in patients with known or suspected coronary artery diseaseIn the modern agehowevercardiac imagi ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government